Engineering Medicines To Improve Patient Care

Scientific Presentations

Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED). This antibody was previously in development as AVE-1642 and was studied in more than 100 oncology patients; the pharmacokinetic, pharmacodynamic, safety, and tolerability data from that program inform our development plans for VRDN-001.

VRDN-001 Scientific Presentations and Publications

Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody for the Treatment of Thyroid Eye Disease

Adobe PDFAmerican Thyroid Association (ATA) Annual Meeting Poster, September 2021

AVE-1642 Scientific Publications

Moreau, P et al. “Phase I study of the anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.”
Leukemia vol. 25,5 (2011): 872-4. doi:10.1038/leu.2011.4
PubMed link: https://pubmed.ncbi.nlm.nih.gov/21321571/

Soria, Jean Charles et al. “A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.”
European Journal of Cancer (Oxford, England : 1990) vol. 49,8 (2013): 1799-807. doi:10.1016/j.ejca.2013.01.003
PubMed link: https://pubmed.ncbi.nlm.nih.gov/23485230/

Macaulay, V. M. et al. “Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.”
Annals of Oncology. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511
PubMed link: https://pubmed.ncbi.nlm.nih.gov/23104723/

VRDN-002 is a distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of Thyroid Eye Disease.

VRDN-002 Scientific Presentations and Publications

VRDN-002, A Second-Generation Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody for TED: Preclinical PK Profile and Clinical Promise

Adobe PDFAmerican Thyroid Association (ATA) Annual Meeting Poster, September 2021